Gemcitabine in low dose in long infusion is a new treatment. Our group was among the first worldwide to introduce this treatment for lung cancer, and especially for patients with squamous carcinoma. Of importance are economic aspects: with only 20% of the normal dose, at least comparable clinical effect has been achieved. The treatment is effective and safe
F.21 Development of new health/diagnostic methods/procedures
COBISS.SI-ID: 23668185New treatment for mesothelioma. The treatment appears superior to any of the currently approved treatments for this disease
F.21 Development of new health/diagnostic methods/procedures
COBISS.SI-ID: 643963